Dare Bioscience, Inc. DARE
Biotechnology: Pharmaceutical Preparations · IPO 2014 · data as of November 13, 2026
Dare Bioscience, Inc. (DARE) is a healthcare company listed in the US with a market value of about $13M. In the twelve months to June 30, 2026 it had revenue of $1M and net income of -$11M, a net margin of -804.4%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -236%.
About Dare Bioscience
Dare Bioscience is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2014. Revenue went from $80000 in 2014 to $1M in 2025, growth of about 26.2% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 59% over three years (dilution for shareholders). It spends 536% of revenue on research and development.
Score: 0.8 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1M | $1M | $9784 | $3M | $10M | $0 | — | — | — | — | $766000 |
| Net income | -$11M | -$13M | -$4M | -$30M | -$31M | -$39M | -$27M | -$14M | -$17M | -$12M | -$672687 |
| Free cash flow | -$12M | -$10M | $5M | -$39M | -$18M | -$29M | -$25M | -$13M | -$10M | -$3M | -$907299 |
| EPS (diluted) | $-0.71 | $-1.20 | $-0.48 | $-4.15 | $-4.44 | $-7.56 | $-10.92 | $-11.64 | $-18.84 | $42.72 | $-9.72 |
| Net margin | -804.4% | -1300.7% | -41430.9% | -1074.2% | -309.5% | — | — | — | — | — | -87.8% |
| ROIC | — | -338.4% | — | — | -270.5% | -100.1% | — | -1156.1% | -187.4% | -84.1% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 3 analysts is $6.33, 863% above the current price; targets range from $2.00 to $12.00; the consensus rating is “none”; expected EPS is $-0.73 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Dare Bioscience pay a dividend?
Not currently.
Is Dare Bioscience a good stock to buy?
We do not give buy or sell advice. Dare Bioscience scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.